---
id: acr-vasculitis-anca-2024
title: "2024 ACR/Vasculitis Foundation Guideline for the Management of ANCA-Associated Vasculitis"
short_title: "ANCA-Associated Vasculitis"
organization: American College of Rheumatology / Vasculitis Foundation
country: United States
url: https://onlinelibrary.wiley.com/doi/10.1002/art.42712
specialty: rheumatology
guideline_type: clinical-practice
evidence_system: acr-grade
conditions:
  - ANCA-Associated Vasculitis
  - Granulomatosis with Polyangiitis
  - Microscopic Polyangiitis
  - Eosinophilic Granulomatosis with Polyangiitis
tags:
  - vasculitis
  - ANCA
  - GPA
  - MPA
  - rituximab
publication_date: 2024-07-01
previous_version_date: 2021-07-08
status: current
supersedes: acr-aav-2021
superseded_by: null
pdf_path: null
has_pdf: false
last_reviewed: 2025-01-01
---

## Scope

This guideline provides updated recommendations for the treatment of ANCA-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).

## Key Recommendations

### Induction - Severe Disease
**GPA/MPA:**
- Rituximab + glucocorticoids (preferred for most patients)
- Cyclophosphamide + glucocorticoids (alternative)
- Avacopan as glucocorticoid-sparing adjunct

**Glucocorticoid Dosing:**
- High-dose initially; taper over 4-6 months
- Avacopan allows reduced glucocorticoid exposure

**Life-Threatening Disease:**
- Add plasma exchange for severe renal/pulmonary involvement (PEXIVAS results considered)

### Induction - Non-Severe Disease
- Methotrexate or mycophenolate + glucocorticoids
- Rituximab for select cases

### EGPA
- Glucocorticoids Â± mepolizumab
- Cyclophosphamide for severe organ involvement
- Rituximab for refractory disease

### Remission Maintenance
- Rituximab preferred over azathioprine/methotrexate
- Duration: At least 18-24 months after remission
- Consider extended maintenance in relapsing disease

**Maintenance Options:**
- Rituximab 500mg every 6 months
- Azathioprine, methotrexate (if rituximab not feasible)

### Monitoring
- ANCA titers (rising may precede relapse but not sole indication for treatment)
- Renal function, urinalysis
- Infection surveillance (PJP prophylaxis during induction)

### Relapse
- Re-induce with rituximab (preferred) or cyclophosphamide
- Glucocorticoids re-intensify temporarily
- Reassess maintenance strategy
